About Cellectar Biosciences (NASDAQ:CLRB)
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease. It also provides CLR 124, a cancer-targeting positron emission tomography imaging PDC for the selective detection of tumors and metastases in a range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. In addition, the company is developing CLR 1601-PTX, CLR 1602-PTX, and CLR 1603-PTX product candidates, which are in pre-clinical research for the treatment of chemotherapy. It has strategic collaboration with Onconova Therapeutics, Inc. to develop phospholipid drug conjugates. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLRB
CUSIPN/A
Phone608-441-8120
Debt
Debt-to-Equity RatioN/A
Current Ratio5.18%
Quick Ratio5.18%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.62 per share
Price / Book1.82
Profitability
EPS (Most Recent Fiscal Year)($1.07)
Net Income$-13,560,000.00
Net MarginsN/A
Return on Equity-143.14%
Return on Assets-118.60%
Miscellaneous
Employees15
Outstanding Shares17,390,000
Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions
What is Cellectar Biosciences' stock symbol?
Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."
How were Cellectar Biosciences' earnings last quarter?
Cellectar Biosciences (NASDAQ:CLRB) released its quarterly earnings data on Wednesday, March, 21st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.11. View Cellectar Biosciences' Earnings History.
When is Cellectar Biosciences' next earnings date?
Who are some of Cellectar Biosciences' key competitors?
Some companies that are related to Cellectar Biosciences include GT Biopharma (GTBP), Elite Pharmaceuticals (ELTP), Oncolytics Biotech (ONCYF), Xenon Pharmaceuticals (XENE), Neurotrope (NTRP), vTv Therapeutics (VTVT), Regulus Therapeutics (RGLS), Axsome Therapeutics (AXSM), Helix Biopharma (HBPCF), Sophiris Bio (SPHS), Vascular Biogenics (VBLT), Scynexis (SCYX), Vernalis (VNLPY), Acerus Pharmaceuti (TRLPF) and Genprex (GNPX).
Who are Cellectar Biosciences' key executives?
Cellectar Biosciences' management team includes the folowing people:
- Mr. James V. Caruso, Chief Exec. Officer, Pres and Director (Age 59)
- Mr. Jarrod Longcor, Chief Bus. Officer (Age 45)
- Mr. John P. Hamill CPA, Interim Chief Financial Officer (Age 54)
- Dr. John E Friend II, M.D., Chief Medical Officer and VP (Age 48)
- Gregory J. Lynch, Sec.
Has Cellectar Biosciences been receiving favorable news coverage?
News stories about CLRB stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectar Biosciences earned a coverage optimism score of 0.12 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 47.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Cellectar Biosciences?
Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellectar Biosciences' stock price today?
One share of CLRB stock can currently be purchased for approximately $1.13.
How big of a company is Cellectar Biosciences?
Cellectar Biosciences has a market capitalization of $19.13 million. The biopharmaceutical company earns $-13,560,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Cellectar Biosciences employs 15 workers across the globe.
How can I contact Cellectar Biosciences?
Cellectar Biosciences' mailing address is 3301 AGRICULTURE DRIVE, MADISON WI, 53716. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]
MarketBeat Community Rating for Cellectar Biosciences (CLRB)
MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe CLRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cellectar Biosciences (NASDAQ:CLRB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | Buy |
| Consensus Rating Score: | N/A | N/A | N/A | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | $2.70 |
| Price Target Upside: | N/A | N/A | N/A | 117.74% upside |
Cellectar Biosciences (NASDAQ:CLRB) Consensus Price Target History
Cellectar Biosciences (NASDAQ:CLRB) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Cellectar Biosciences (NASDAQ:CLRB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cellectar Biosciences (NASDAQ CLRB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.17%
Institutional Ownership Percentage: 7.61%
Cellectar Biosciences (NASDAQ CLRB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/13/2018 | Jarrod Longcor | Insider | Sell | 13,000 | $1.18 | $15,340.00 | 67,000 |  |
| 3/12/2018 | James V Caruso | CEO | Sell | 34,000 | $1.20 | $40,800.00 | 213,548 | |
| 11/14/2017 | John Neis | Director | Sell | 5,214 | $1.49 | $7,768.86 | | |
| 11/29/2016 | John Neis | Director | Buy | 333,333 | $1.49 | $496,666.17 | | |
| 10/31/2016 | Richard Hertzberg | Insider | Sell | 21,000 | $2.03 | $42,630.00 | 280,000 | |
| 4/20/2016 | James V Caruso | CEO | Buy | 46,948 | $2.12 | $99,529.76 | 47,548 | |
| 4/20/2016 | Paul L Berns | Director | Buy | 117,371 | $2.12 | $248,826.52 | 117,371 | |
| 12/31/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 100,000 | $0.69 | $69,000.00 | | |
| 12/29/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 82,847 | $0.69 | $57,164.43 | | |
| 12/28/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 367,966 | $0.73 | $268,615.18 | | |
| 12/22/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 7,938 | $0.90 | $7,144.20 | | |
| 12/21/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 27,621 | $0.92 | $25,411.32 | | |
| 12/17/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 71,225 | $0.87 | $61,965.75 | | |
| 12/15/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 44,965 | $0.82 | $36,871.30 | | |
| 12/4/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 50,950 | $1.06 | $54,007.00 | | |
| 11/24/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 173,802 | $1.24 | $215,514.48 | | |
| 11/24/2015 | James V Caruso | CEO | Buy | 1,000 | $1.30 | $1,300.00 | 6,000 | |
| 11/20/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 96,806 | $1.17 | $113,263.02 | | |
| 11/20/2015 | James V Caruso | CEO | Buy | 1,000 | $1.16 | $1,160.00 | 5,000 | |
| 11/19/2015 | James V. Caruso | CEO | Buy | 4,000 | $1.45 | $5,800.00 | 4,000 | |
| 10/23/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 8,866 | $2.00 | $17,732.00 | | |
| 10/6/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 2,554 | $2.00 | $5,108.00 | | |
| 10/5/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 7,500 | $2.04 | $15,300.00 | | |
| 10/1/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 27,940 | $2.05 | $57,277.00 | | |
| 9/29/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 24,801 | $2.36 | $58,530.36 | | |
| 8/20/2014 | John Neis | Director | Buy | 268,711 | $3.75 | $1,007,666.25 | | |
| 8/20/2014 | Simon Pedder | CEO | Buy | 13,300 | $3.75 | $49,875.00 | | |
(Data available from 1/1/2013 forward)
Cellectar Biosciences (NASDAQ CLRB) News Headlines
| Source: |
|
Cellectar Biosciences (NASDAQ:CLRB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cellectar Biosciences (NASDAQ:CLRB) Income Statement, Balance Sheet and Cash Flow Statement
Cellectar Biosciences (NASDAQ CLRB) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
